Geptanolimab is under clinical development by Apollomics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Geptanolimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Geptanolimab (CBT-501) is under development for the treatment of cancers such as melanoma, renal cell carcinoma, head and neck cancer, bladder cancer, ovarian cancer, colorectal cancer, gastric cancer, soft tissue sarcoma, ALK-negative anaplastic large cell lymphoma, endometrial cancer, metastatic cervical cancer, spongioblastoma, non-small cell lung cancer, mesothelioma, esophageal cancer, nasopharyngeal cancer, gastroesophageal junction adenocarcinoma and lymphomas including classical Hodgkin lymphoma, peripheral T-cell lymphoma, NK-T cell lymphoma and mediastinal B cell lymphoma. It is administered through intravenous infusion. The drug candidate is an IgG4 humanized monoclonal antibody against programmable death-1 (PD-1).
It was also under development for the treatment of metastatic hepatocellular carcinoma, thymic carcinoma and metastatic renal cell carcinoma.
Apollomics formerly CBT Pharmaceuticals, is a biotechnology company that discovers and develops oncology therapies. It is investigating APL-101, a novel small molecule c-Met inhibitor (c-METi) that targets the c-Met-dysregulated pathway in gastric, hepatic, pancreatic and lung tumors; and APL-102, an oral multi kinase inhibitor (mKi) targeting receptor tyrosine kinase (RTKs) and serine or threonine-kinases in liver, breast, colorectal, gastric cancers. The company is also evaluating APL-106 against acute myeloid leukemia (AML); APL-108 to treat multiple myeloma (MM); APL-501 and APL-102 targeting solid tumors; APL-502 and APL-801 against multiple tumors; and APL-810 for gastroenterological cancers. It operates in Taiwan and the US. Apollomics is headquartered in Pleasanton, California, the US.
For a complete picture of Geptanolimab’s drug-specific PTSR and LoA scores, buy the report here.